StockData
Aura Biosciences, Inc. logo

Aura Biosciences, Inc. (AURA) stock

AURANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$7.14−0.01 (-0.14%)

Close on Nov 18, 2026Market cap $740.45MP/E –Yield –

Aura Biosciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Aura Biosciences's free cash flow for the twelve months ending Jun 30, 2026 was -$103.35M. For fiscal 2025 it was -$85.19M. The highest annual figure on record is -$25.09M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$85.19M–
FY2024Dec 31, 2024-$81.06M–
FY2023Dec 31, 2023-$64.56M–
FY2022Dec 31, 2022-$55.70M–
FY2021Dec 31, 2021-$34.54M–
FY2020Dec 31, 2020-$25.09M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$32.52M–
Q1 FY2026Mar 31, 2026-$30.00M–
Q4 FY2025Dec 31, 2025-$20.65M–
Q3 FY2025Sep 30, 2025-$20.19M–
Q2 FY2025Jun 30, 2025-$20.81M–
Q1 FY2025Mar 31, 2025-$23.54M–
Q4 FY2024Dec 31, 2024-$24.25M–
Q3 FY2024Sep 30, 2024-$15.61M–
Q2 FY2024Jun 30, 2024-$16.65M–
Q1 FY2024Mar 31, 2024-$24.54M–
Q4 FY2023Dec 31, 2023-$17.70M–
Q3 FY2023Sep 30, 2023-$15.49M–
Q2 FY2023Jun 30, 2023-$14.84M–
Q1 FY2023Mar 31, 2023-$16.52M–
Q4 FY2022Dec 31, 2022-$18.37M–
Q3 FY2022Sep 30, 2022-$10.82M–
Q2 FY2022Jun 30, 2022-$10.70M–
Q1 FY2022Mar 31, 2022-$15.80M–
Q4 FY2021Dec 31, 2021-$12.91M–
Q3 FY2021Sep 30, 2021-$9.26M–
Q2 FY2021Jun 30, 2021-$7.16M–
Q1 FY2021Mar 31, 2021-$5.21M–
Q4 FY2020Dec 31, 2020-$3.89M–

More Aura Biosciences figures

See a number that looks wrong?